A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|December 1, 2005
- Volume 0 0
FDA Reviews Trexima for Treatment of Migraines
Author(s)Susan Farley
Advertisement
GlaxoSmithKline and POZEN Inc announced that the drugTrexima will be reviewed by the FDA for the acute treatmentof migraine headaches. The companies have proposed Treximaas the brand name for their combination of sumatriptansuccinate (Imitrex) and naproxen sodium (Aleve, for example)in a single-tablet form. Pending approval by the FDA, Treximacould be available to the public by the second half of 2006.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Articles in this issue
almost 21 years ago
CAN YOU READ THESE Rxs?almost 21 years ago
Bar Coding Thwarts Illegitimate Drug Usealmost 21 years ago
COMPREHENSIVE CARE CLINIC: DIABETES: Diabetes-related Stress and Depressionalmost 21 years ago
Hypertension Counseling Requires a Multifactorial Approachalmost 21 years ago
COMPOUNDING HOTLINEalmost 21 years ago
Pharmacy Law: Duty to Warn Waived When Patient Refuses Counselingalmost 21 years ago
EnterpriseRx Pharmacy Management Systemalmost 21 years ago
Hospital Installs Automated Medication Cabinetsalmost 21 years ago
"Smartphones" Help with Clinical Trial Informationalmost 21 years ago
HIT Needs Medicare's LeadershipAdvertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5